目的 探討厄洛替尼致睫毛異常生長(zhǎng)的發(fā)生情況和臨床特點(diǎn),為其臨床安全用藥提供參考。方法 檢索中國(guó)知網(wǎng)(CNKI)、維普中文科技期刊數(shù)據(jù)庫(kù)(VIP)、萬(wàn)方數(shù)據(jù)庫(kù)、PubMed、Medline數(shù)據(jù)庫(kù)2004年1月-2022年2月收錄的厄洛替尼致睫毛異常生長(zhǎng)相關(guān)文獻(xiàn),進(jìn)行統(tǒng)計(jì)分析。結(jié)果 納入統(tǒng)計(jì)文獻(xiàn)共21篇,涉及26例患者,其中,60歲以上老年患者17例,占比65.38%;患者睫毛異常生長(zhǎng)多發(fā)生于用藥后6個(gè)月內(nèi)(20例),占比76.92%;臨床表現(xiàn)方面,睫毛異常增長(zhǎng)伴卷曲、倒睫引發(fā)角膜刺激征5例,出現(xiàn)瞼板腺堵塞、眼瞼炎和不自主流淚2例,導(dǎo)致嚴(yán)重的眼部損害癥狀,如角膜潰瘍、糜爛及視覺(jué)障礙4例;經(jīng)積極對(duì)癥處理或停藥后得到解決的患者21例;未予處理5例。結(jié)論 厄洛替尼引發(fā)睫毛異常生長(zhǎng)并非厄洛替尼的限制性副作用,但任其發(fā)展,可引發(fā)倒睫、眼角膜上皮損傷,進(jìn)而出現(xiàn)角膜潰瘍、穿孔等,最終可致盲。故臨床醫(yī)師應(yīng)嚴(yán)格按照適應(yīng)證及推薦劑量給藥,重視厄洛替尼引發(fā)的睫毛異常生長(zhǎng)導(dǎo)致的嚴(yán)重后果。

Objective Investigate the occurrence and clinical characteristics of abnormal eyelash growth caused by erlotinib, so as to provide reference for using it on clinical aspects safely. Methods Literatures related to abnormal eyelash growth caused by erlotinib collected by CNKI, VIP, Wanfang, PubMed, and Medline database as of Feburary 2022 were searched for statistical analysis. Results A total of 21 statistical literatures were included, involving 26 patients. Among them, the proportion of elderly patients over 60 years old was the highest (19 cases), accounting for 65.38%. The abnormal growth of eyelashes occurred within 6 months after treatment (20 cases), accounting for 76.92%. In terms of clinical manifestations, abnormal growth of eyelashes with curl and trichiasis caused corneal irritation in 5 cases, tarsal gland blockage, blepharitis, and involuntary tears in 2 cases, resulting in serious ocular damage symptoms, such as corneal ulcer, erosion and visual impairment in 4 cases. 21 Cases were solved after active symptomatic treatment or drug withdrawal; 5 cases were not treated. Conclusion Abnormal eyelash growth caused by erlotinib is not the limiting side effect of erlotinib, but its development can lead to trichiasis, corneal epithelial damage, corneal ulcer, perforation, etc., and finally blindness. Therefore, clinicians should strictly follow the indications and recommended dose, and pay attention to the serious consequences caused by abnormal eyelash growth caused by erlotinib.

R979.1